Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Moleculin Announces Closing of up to $16.5 Million Public Offering
-
Moleculin (MBRX) Prices 7.04M Share Offering at $0.64/sh
-
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
-
Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
-
Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
-
Moleculin Biotech (MBRX) PT Lowered to $14 at Maxim Group, Following Clinical Update
-
Moleculin Announces Full Exercise of Over-Allotment Option
-
Moleculin Biotech (MBRX) Prices 14.27M Share Common Offering at $4.75/Sh
-
Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering
-
Moleculin to Speak on COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference
-
UPDATE: Moleculin Biotech (MBRX) Announces $6M Registered Direct Offering at $0.80/Unit
-
Moleculin Announces $6.0 Million Registered Direct Offering
-
Moleculin Biotech (MBRX) Prices 9.375M Unit Offering at $1.60/Unit
-
Moleculin Announces $15.0 Million Registered Direct Offering
-
Moleculin Biotech (MBRX) Prices Underwritten Public Offering of Common Stock and Warrants
-
Moleculin Announces Pricing Of Underwritten Public Offering
-
Moleculin Biotech (MBRX) Enrolled It First Two Patients In European Clinical Trial - Maxim
-
Maxim Group Starts Moleculin Biotech (MBRX) at Buy
